SMAD-CC: SMArt Data for improved machine learning in Cancer Care

Paul MINCHELLA1,2, Dounya BOURHANI1,2, Elieel KATCHE1, Stephane CHRETIEN1, Guillaume METZLER2, Loic VERLINGUE1

CRCL - Centre Léon Berard, 29 Rue Gabriel Sarrazin, 69008 LYON
ERICLAB Lyon2, 5 Avenue Pierre Mendès France, 69500 BRON

CONTTEXTE
SMAD-CC proposes to combine clinical, biological and molecular data with medical reports, for patients with various cancers. Our main objective is to improve the quality and completeness of data available to predict patient survival and evaluate the effects of medical interventions. This involves using various types of data at different points in the patient’s history. We will then train our model on clinical reports using Natural Language Processing (NLP), and compare the performance of the data enrichment process. The Expected results include a demonstration of the added value of recent advances in robust statistics and machine learning theory. SMAD-CC is at the forefront of multimodal artificial intelligence for personalized cancer care, with many possible impacts on research and clinical application in this field.

Patient seen during hospitalization for treatment.
The clinical examination is unchanged.
The biological assessment is good.

Risk benefit:
We are therefore administering today on the VVP the first cycle of CABAZITAXEL at a dose of 28 mg/m² for his castration-resistant metastatic prostate. I had already given him all the prescriptions. I plan to have a CT scan and a bone scan after 4 treatment courses.